Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L-Reference-Cited by-同舟云学术

Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L

Published:2022-02-22 Issue:5 Volume:65 Page:3943-3961
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Prigaro Brett J.¹,Esquer Hector¹,Zhou Qiong¹,Pike Laura A.¹,Awolade Paul¹^ORCID,Lai Xin-He¹,Abraham Adedoyin D.¹,Abbott Joshua M.¹,Matter Brock¹,Kompella Uday B.¹²,Messersmith Wells A.³²⁴,Gustafson Daniel L.⁵²⁴,LaBarbera Daniel V.¹²⁴^ORCID

Affiliation:

1. The Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, The CU Cancer Center, Aurora, Colorado 80045, United States

2. The University of Colorado (CU) Anschutz Medical Campus (AMC) Center for Drug Discovery, The CU Cancer Center, Aurora, Colorado 80045, United States

3. The School of Medicine, Division of Medical Oncology, The CU Cancer Center, Aurora, Colorado 80045, United States

4. The CU Cancer Center, Aurora, Colorado 80045, United States

5. Flint Animal Cancer Center and Department of Clinical Sciences, School of Biomedical Engineering, Colorado State University, Fort Collins, Colorado 80523, United States

Funder

National Cancer Institute

University of Colorado

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c01778

Reference38 articles.

1. Poly(ADP-ribose)–Dependent Regulation of DNA Repair by the Chromatin Remodeling Enzyme ALC1

2. Isolation and characterization of a novel oncogene, amplified in liver cancer 1, within a commonly amplified region at 1q21 in hepatocellular carcinoma